MX353602B - Composiciones, métodos y usos para inducir el crecimiento viral. - Google Patents

Composiciones, métodos y usos para inducir el crecimiento viral.

Info

Publication number
MX353602B
MX353602B MX2015008630A MX2015008630A MX353602B MX 353602 B MX353602 B MX 353602B MX 2015008630 A MX2015008630 A MX 2015008630A MX 2015008630 A MX2015008630 A MX 2015008630A MX 353602 B MX353602 B MX 353602B
Authority
MX
Mexico
Prior art keywords
compositions
methods
inducing
growth
viral growth
Prior art date
Application number
MX2015008630A
Other languages
English (en)
Inventor
Dan T Stinchcomb
Jill A Livengood
O'neil Wiggan
Richard Kinney
Jorge Osorio
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of MX353602B publication Critical patent/MX353602B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

La presente invención se refiere a un método para manufacturar virus de ARN y ADN envueltos, el método comprendiendo: crecer células huésped; introducir a las células huésped una composición que comprende medios para crecer cultivos virales que comprenden uno o más copolímeros de bloque de óxido de etileno u óxido de propileno (OE-OP) antes, durante o después de la infección viral de las células huésped; el uno o más copolímeros de bloque OE-OP comprendiendo poloxámero 407, poloxámero 403 o una combinación de los mismos, en donde la concentración del uno o más copolímeros de bloque OE-OP es de 0.001% a 3.0%; introducir virus a las células huésped antes, durante o después de la introducción de la composición; incubar las células huésped, los virus y el medio durante un periodo predeterminado; separar el medio de las células huésped; y recolectar los virus del medio.
MX2015008630A 2008-12-05 2011-06-03 Composiciones, métodos y usos para inducir el crecimiento viral. MX353602B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12026208P 2008-12-05 2008-12-05

Publications (1)

Publication Number Publication Date
MX353602B true MX353602B (es) 2018-01-19

Family

ID=42231513

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011005886A MX2011005886A (es) 2008-12-05 2009-12-04 Composiciones, métodos y usos para inducir el crecimiento viral.
MX2015008630A MX353602B (es) 2008-12-05 2011-06-03 Composiciones, métodos y usos para inducir el crecimiento viral.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2011005886A MX2011005886A (es) 2008-12-05 2009-12-04 Composiciones, métodos y usos para inducir el crecimiento viral.

Country Status (20)

Country Link
US (3) US8871487B2 (es)
EP (1) EP2366024B1 (es)
JP (2) JP5728742B2 (es)
KR (1) KR101784951B1 (es)
CN (2) CN105219734B (es)
AR (1) AR074483A1 (es)
AU (1) AU2009322175B2 (es)
BR (2) BR122020015754B8 (es)
CA (1) CA2745962C (es)
CO (1) CO6390063A2 (es)
CU (1) CU20110128A7 (es)
HR (1) HRP20191324T1 (es)
IL (2) IL213389B (es)
MX (2) MX2011005886A (es)
MY (1) MY178195A (es)
NZ (1) NZ593415A (es)
SG (3) SG10201503671TA (es)
TW (2) TWI573874B (es)
WO (1) WO2010065911A1 (es)
ZA (2) ZA201104364B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI573874B (zh) 2008-12-05 2017-03-11 武田疫苗股份有限公司 用於誘導病毒生長之組成物、方法及用途
EP2746386A1 (en) * 2012-12-21 2014-06-25 Lonza Cologne GmbH Materials and methods for cell culture
CN107429234A (zh) * 2015-03-30 2017-12-01 味之素株式会社 含人血清白蛋白的神经干细胞增殖培养基
WO2023147337A2 (en) * 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
US5616487A (en) * 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
JP2000517188A (ja) * 1996-08-30 2000-12-26 ライフ テクノロジーズ，インコーポレイテッド 無血清哺乳動物細胞培養培地およびその使用
AU4556597A (en) * 1996-09-24 1998-04-17 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
CN1257169C (zh) 1999-10-08 2006-05-24 格吕伦塔尔有限公司 双环咪唑－3－基－胺衍生物
EP3000477A1 (en) * 2000-02-16 2016-03-30 The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, Avirulent, immunogenic flavivirus chimeras
WO2003060088A2 (en) * 2002-01-15 2003-07-24 Acambis, Inc. Viral vaccine production method
CA2478932A1 (en) * 2002-03-29 2003-10-16 Merck & Co., Inc. Large scale methods of producing adenovirus and adenovirus seed stocks
RU2237065C2 (ru) 2002-10-03 2004-09-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека
PL199642B1 (pl) * 2002-11-15 2008-10-31 Inst Immunologii I Terapii Do Preparat bakteriofagowy o podwyższonej trwałości oraz zastosowanie blokowego kopolimeru tlenku etylenu i tlenku propylenu
EP2078201A2 (en) * 2006-10-05 2009-07-15 Agency for Science, Technology and Research Dengue diagnosis and treatment
KR101562971B1 (ko) * 2007-04-06 2015-10-23 다케다 백신즈 인코포레이티드 살아있는 약독화된 바이러스를 위한 방법 및 조성물
US8367370B2 (en) * 2008-02-11 2013-02-05 Wheeler Aaron R Droplet-based cell culture and cell assays using digital microfluidics
TWI573874B (zh) * 2008-12-05 2017-03-11 武田疫苗股份有限公司 用於誘導病毒生長之組成物、方法及用途

Also Published As

Publication number Publication date
ZA201600550B (en) 2021-08-25
SG10201503671TA (en) 2015-06-29
TWI573874B (zh) 2017-03-11
CN105219734B (zh) 2020-03-03
BRPI0922788A8 (pt) 2017-12-12
US20100144015A1 (en) 2010-06-10
HRP20191324T1 (hr) 2019-10-18
SG10202007719TA (en) 2020-09-29
TW201030148A (en) 2010-08-16
TW201514302A (zh) 2015-04-16
MX2011005886A (es) 2011-07-28
BRPI0922788A2 (pt) 2015-08-18
MY178195A (en) 2020-10-06
US20150010983A1 (en) 2015-01-08
JP2015109874A (ja) 2015-06-18
AR074483A1 (es) 2011-01-19
JP6174066B2 (ja) 2017-08-02
WO2010065911A1 (en) 2010-06-10
ZA201104364B (en) 2022-10-26
IL238819A (en) 2017-08-31
KR101784951B1 (ko) 2017-10-12
CU20110128A7 (es) 2012-06-21
US8871487B2 (en) 2014-10-28
IL238819A0 (en) 2015-06-30
EP2366024A4 (en) 2012-07-04
CA2745962A1 (en) 2010-06-10
JP5728742B2 (ja) 2015-06-03
SG171972A1 (en) 2011-07-28
US20180251737A1 (en) 2018-09-06
TWI461536B (zh) 2014-11-21
US9890362B2 (en) 2018-02-13
IL213389A0 (en) 2011-07-31
IL213389B (en) 2018-10-31
CN102272294A (zh) 2011-12-07
CO6390063A2 (es) 2012-02-29
BR122020015754B8 (pt) 2021-04-06
CN102272294B (zh) 2015-09-02
EP2366024A1 (en) 2011-09-21
BR122020015754B1 (pt) 2021-03-23
BRPI0922788B1 (pt) 2021-03-23
BRPI0922788B8 (pt) 2021-05-25
NZ593415A (en) 2014-04-30
CN105219734A (zh) 2016-01-06
EP2366024B1 (en) 2019-05-01
AU2009322175B2 (en) 2014-10-09
CA2745962C (en) 2018-11-27
JP2012510822A (ja) 2012-05-17
KR20110127117A (ko) 2011-11-24
AU2009322175A1 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
MY165955A (en) Methods of reducing hair loss and/or facilitating hair growth and/or regrowth
MY179933A (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use thereof
MY166789A (en) Arginine salts and their uses for the treatment of illnesses in the oral cavity
SG196784A1 (en) Stem cell cultures
WO2009151907A3 (en) Compositions and methods for using cells to treat heart tissue
MX2012000396A (es) Metodos y composiciones para uso en tartamientos celulares.
PH12014501369A1 (en) Oral care compositions
IN2012DN00581A (es)
NZ611531A (en) Bovine viral diarrhea virus type 1b vaccine compositions and methods
MX353602B (es) Composiciones, métodos y usos para inducir el crecimiento viral.
EP2435558A4 (en) PRODUCTION OF HEAVY INDUCED PLURIPOTENT STEM CELLS GENERALLY CORRECTED
WO2011019641A3 (en) Nutritional compositions including exogenous nucleotides
MX337070B (es) Método para preparar un conjugado klh-egfrviii.
MY161460A (en) Elastomeric dental floss
EP2501405A4 (en) COMPOSITION, METHOD, AND USES OF POX VIRUS ELEMENTS IN VACCINATE CONSTRUCTS
UA41936U (ru) Способ лечения крауроза вульвы в детском возрасте
MX2010010016A (es) Preparacion de composicion farmaceutica para aumentar densidad mineral osea.
UA35047U (ru) Способ проведения оздоровительной гимнастики
MY167173A (en) Oral care compositions
UA47384U (en) Sambuka klasychna, liqueur beverage
UA50791U (ru) МАТЕРИАЛ ДЛЯ термоэлементов
UA44840U (ru) Способ формирования межкишечного анастомоза по типу "бок в бок"
UA47385U (ru) Ликерный напиток "самбука классическая голубая"
NZ720788A (en) Eczema treatment
TH129815B (th) องค์ประกอบ, วิธีการและการใช้เพื่อการเร่งการเจริญเติบโตของไวรัส